Cargando…
Molecular Targets for the Treatment of Metastatic Colorectal Cancer
Over the past years, colorectal cancer (CRC) was subtyped according to its molecular and genetic characteristics, allowing the development of therapeutic strategies, based on predictive biomarkers. Biomarkers such as microsatellite instability (MSI), RAS and BRAF mutations, HER2 amplification or NTR...
Autores principales: | Cohen, Romain, Pudlarz, Thomas, Delattre, Jean-François, Colle, Raphaël, André, Thierry |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563268/ https://www.ncbi.nlm.nih.gov/pubmed/32825275 http://dx.doi.org/10.3390/cancers12092350 |
Ejemplares similares
-
Immune Checkpoint Inhibition in Metastatic Colorectal Cancer Harboring Microsatellite Instability or Mismatch Repair Deficiency
por: Cohen, Romain, et al.
Publicado: (2021) -
Treatments after Immune Checkpoint Inhibitors in Patients with dMMR/MSI Metastatic Colorectal Cancer
por: Bui, Quang Loc, et al.
Publicado: (2022) -
Adrenal gland as a sanctuary site for immunotherapy in patients with microsatellite instability-high metastatic colorectal cancer
por: Cohen, Romain, et al.
Publicado: (2021) -
Molecularly targeted drugs for metastatic colorectal cancer
por: Cheng, Ying-dong, et al.
Publicado: (2013) -
Targetable Molecular Alterations in the Treatment of Biliary Tract Cancers: An Overview of the Available Treatments
por: Valery, Marine, et al.
Publicado: (2023)